Healthcare Professionals

Fulcrum Therapeutics, Inc.  a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically defined rare diseases, announced that FTX-6058, its investigational treatment for sickle cell disease (SCD) and…

CTX001, an investigational gene-editing cell therapy, has been granted priority medicines (PRIME) designation by the European Medicines Agency (EMA) for the treatment of severe sickle cell disease (SCD). The announcement was made by CRISPR Therapeutics and Vertex Pharmaceuticals, which are jointly…

Tune in with TIF on Tuesday, 15 September 2020, 15:00 EEST, for one of the last webinars from the TIF eThalED series for Healthcare Professionals! The topic to be brought…

Due to some difficulties and restrictions encountered as a result of the COVID-19 pandemic, the Renzo Galanello Fellowship Programme 2020 will not be offered in its full length and as initially…

One of the leading COVID-19 vaccine candidates currently in development is getting closer to a potential finish line. Pfizer said on Wednesday that the recruitment for the crucial U.S. phase 3 clinical…

Malaysia needs more geneticists in order to identify thalassaemia patients at an early stage, stated Health Minister Datuk Seri Dr Adham Baba, after launching the 2019 Malaysia Thalassaemia Registry (MTR)…

TIF´s upcoming webinar on ”Iron Monitoring in Thalassaemia”, specially designed and launched for medical specialists and healthcare professionals with a particular interest in the field of haemoglobin disorders and thalassaemia,…